Skip to main
  1. Stocks
  2. Unicycive Therapeutics
  3. Forecast
UNCY

Unicycive Therapeutics (UNCY) Stock Forecast & Price Target

Unicycive Therapeutics (UNCY) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Unicycive Therapeutics is attractive fundamentally because the FDA has raised no efficacy or safety concerns for oxylanthanum carbonate, and the latest NDA resubmission shifted the remaining issue toward a more addressable manufacturing/compliance fix using a new third-party vendor with a March 2024 NAI inspection and 12-month stability data. The company also has meaningful commercial leverage if approved, since TDAPA could pay at 100% of ASP for two years outside the ESRD bundle, with modeling pointing to FY2027 revenue of $27.5M and risk-adjusted FY27/FY28 revenues of $102M/$399M alongside peak U.S. net sales near $400M in 2028E. Financially, cash and marketable securities of $61.4M and runway into 2H27 reduce near-term financing pressure, while the clean balance sheet and warrant milestones support upside if FDA inspection and approval timelines improve.

Bears say

Unicycive Therapeutics is a clinical-stage biotech with no product revenue and a history of significant operating losses, leaving it unlikely to reach GAAP profitability or positive cash flow until 2027 and dependent on external funding. Its balance sheet is stretched, with about $61M in cash at the end of 2Q 2026 and $102M in warrant commitments, but those tranches could add up to 15.8M shares of dilution while still not eliminating the need for more capital. The investment case also hinges on OLC overcoming binary FDA, manufacturing, reimbursement, and commercial adoption risks, while delayed approval to late 2026 and slower TDAPA timing to mid 2027 imply a more uncertain and potentially weaker sales ramp.

Unicycive Therapeutics (UNCY) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Unicycive Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction

Get the latest Unicycive Therapeutics (UNCY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Unicycive Therapeutics (UNCY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Unicycive Therapeutics (UNCY) Forecast

Analysts have given Unicycive Therapeutics (UNCY) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Unicycive Therapeutics (UNCY) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Unicycive Therapeutics (UNCY)


Unicycive Therapeutics (UNCY) Analyst Forecast & Price Prediction

Get the latest Unicycive Therapeutics (UNCY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Unicycive Therapeutics (UNCY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover UNCY stock data and trends